Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dynavax Names Denise M. Gilbert to Board of Directors
Dynavax Names Denise M. Gilbert to Board of Directors BERKELEY, Calif., March 8 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that Denise M. Gilbert, Ph.D., has joined its Board of Directors. Dr. Gilbert will also serve as chair of the Board's Audit
View HTML
Toggle Summary Dynavax Names D. Kevin Kwok, Vice President and Chief Business Officer
Dynavax Names D. Kevin Kwok, Vice President and Chief Business Officer BERKELEY, Calif., March 4 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today announced the appointment of D. Kevin Kwok, Pharm.D., to the position of vice president and chief business officer.
View HTML
Toggle Summary Dynavax Initiates Phase II/III Clinical Trial for Ragweed Allergy Immunotherapy
Dynavax Initiates Phase II/III Clinical Trial for Ragweed Allergy Immunotherapy Dynavax Initiates Phase II/III Clinical Trial for Ragweed Allergy Immunotherapy BERKELEY, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today the start of a
View HTML
Toggle Summary Dynavax Announces Exercise of Underwriters' Over-Allotment Option
Dynavax Announces Exercise of Underwriters' Over-Allotment Option BERKELEY, Calif., Feb. 24 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), today announced that the underwriters of its previously announced initial public offering of 6,000,000 shares of common stock have
View HTML
Toggle Summary Dynavax Prices IPO at $7.50 Per Share
Dynavax Prices IPO at $7.50 Per Share BERKELEY, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) announced today that it has priced its initial public offering of 6,000,000 shares of its common stock at $7.50 per share, below the estimated range.
View HTML
Toggle Summary Dynavax Announces Strategic Partnering Agreement With UCB Pharma for Development and Commercialization of Seasonal Allergy Products
Dynavax Announces Strategic Partnering Agreement With UCB Pharma for Development and Commercialization of Seasonal Allergy Products Berkeley, CA - February 5, 2004 - Dynavax Technologies Corporation announced today that it has entered into an agreement with UCB Pharma, the pharmaceuticals division
View HTML
Toggle Summary Dynavax Announces USPTO Declaration of Interference to Resolve Inventorship of ISS Intelectual Property
Dynavax Announces USPTO Declaration of Interference to Resolve Inventorship of ISS Intelectual Property Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - December 18, 2003 - Dynavax Technologies Corporation, a privately
View HTML
Toggle Summary Dynavax Technologies and Berna Biotech Announce Collaboration
Dynavax Technologies and Berna Biotech Announce Collaboration Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berna Biotech Ltd Béatrice Keller Communications Manager communications@bernabiotech.com Phone +41 (0) 31 980 6522 Fax +41 (0)
View HTML
Toggle Summary Dynavax Technologies Corporation Files Registration Statement for Initial Public Offering
Dynavax Technologies Corporation Files Registration Statement for Initial Public Offering Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - October 24, 2003 - Dynavax Technologies Corporation announced today that it has
View HTML
Toggle Summary Dynavax Names Daniel Levitt Vice President and Chief Medical Officer
Dynavax Names Daniel Levitt Vice President and Chief Medical Officer Contact: Dino Dina, M.D. President and Chief Executive Officer Dynavax Technologies Corporation (510) 848-5100 Berkeley, CA - August 4, 2003 - Dynavax Technologies Corporation today announced the appointment of Daniel Levitt,
View HTML